Fennec Pharmaceuticals develops and sells PEDMARK, a sodium thiosulfate injection, from Research Triangle Park, North Carolina. FENC reports earnings on Thu, Nov 12, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for FENC are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in FENC in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FENC is in one of them and how their past FENC trades turned out.
Fennec Pharmaceuticals is a pharmaceutical company based in Research Triangle Park, North Carolina. Its main product is PEDMARK, a sodium thiosulfate injection that the company develops and commercializes. The company relies on patents and licensed intellectual property to protect PEDMARK from competing generic versions. It works with licensors and collaborators on its technologies and product.
